abstract |
The present invention describes sulfodexide or one or more constituents thereof for use in the reduction of circulating matrix metalloproteinases (MMPs), in particular MMP-9. The sulfodexide or its components may include cardiovascular diseases, cardiovascular diseases caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, lung diseases, and neoplastic pathology. This is useful for the treatment of pathologies involving MMPs. |